Clinical Trial Detail

NCT ID NCT02738866
Title Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Palbociclib

Age Groups: senior adult

Additional content available in CKB BOOST